Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

25-04-2024(Thu) 24-04-2024(Wed) 23-04-2024(Tue) 22-04-2024(Mon) 19-04-2024(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
20 Oct, 2016 (Thursday)

            
ANTON OILFIELD(3337)
Analysis¡G
Anton Oilfield Services Group (3337) has issued the operational update on the third quarter of 2016 and outlook for the fourth quarter. During the third quarter, the Group was awarded new orders worth approximately RMB393 million. Year to date, it had secured new orders worth approximately RMB1.86 billion. As of September 2016, its order backlog was worth approximately RMB3.6 billion, of which the order backlog in the domestic market was approximately RMB1.03 billion and the order backlog in the overseas market was approximately RMB2.56 billion. It signals that the international oil market is gradually showing signs of recovery and the worst may be over. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $1.00, Target Price: $1.20, Cut Loss Price: $0.90

KPC Pharmaceuticals(600422)
Analysis¡G
During the past ten years, the operating results of KPC Pharmaceuticals have basically maintained a high growth rate of over 20%, except in 2008 and 2014 when the growth rate went below 20%. Though the result was not as good as expected in 1H16, we keep optimistic about the mid- and long-term development of the company. There is still large space for the development of the Company`s Kunming traditional Chinese medicines and Xuesaitong Soft Capsules, etc. Concurrently, the Company focuses on creating the chronic disease management system, speeds up its medical business layout and shows a strong intention to engage in epitaxial mergers. The company has continuously pushed forward its refined marketing reform, set up new business departments like OTC, increased investment in the marketing business line integration and channel penetration, and strengthened incentives for frontline personnel. The Company`s marketing advantages are expected to be intensified. Besides, the Company plans to release "Liver-Soothing Granules and Xiangsha Pingwei Granules" as the golden prescription drugs and "Banlan Qingre Granules, Shenling Jianpiwei Granules, and Qingfei Huatan Pills" as the golden OTC drugs. Resources will be pooled to make a breakthrough in the sales volume of these five golden products and further drive the speedy increase in the botanical drug series.
Strategy¡G
Buy-in Price: $14.27, Target Price: $15.50, Cut Loss Price: $13.80


BAIC (1958.HK) - Updates¡Gmaintain the ``Buy``rating

Nearly 20% Increase in Total Sales in the First Three Quarters

In the first nine months of this year, the total number of vehicles sold by BAIC Motor recorded 1,315,362 units, representing a year-on-year increase of approximately 19%, better than the industry average. To be specific, the sales of Beijing Benz witnessed a substantial year-on-year increase of 29% to 226,795 units. Besides, the sales of independent brands skyrocketed by 51% to 309,567 units compared with that of the last year. And the sales of Beijing Hyundai grew by 7.5% over last year to 779,000 units. The strong rise of Beijing Benz was primarily because it was in the strong product cycle and its new products were well received by the market upon launch. The growth of proprietary brand was because it unveiled a number of new SUVs based on the booming domestic SUV market and the SUV sales soared by eight times to 156,160 units. Currently, the only less ideal Beijing Hyundai seems to show a gradually stable trend.

Sales of Blade Electric Vehicles Remained Number One

It is worth mentioning that the performance of new energy vehicles, the market focus, was the highlight. The sales of new energy vehicles under BAIC Motor brands amounted to about 30,274 units in the first nine months of 2016, up by 169% over the previous year and remained number one in the sales of pure electric vehicles nationwide. When it comes to the future planning for new energy vehicle models, according to the management of BAIC BJEV, A00-class sedan coded `C10` and B-class sedan coded `C80` would be launched around this October, and ARCFOX-1 would be released at the end of this year and officially listed on the market in the first half of next year. Also, EX300L displayed in the Beijing International Automotive Exhibition would also be unveiled next year. A vast range of new vehicles and addition of the first product of ARCFOX are expected to consolidate and continue improving the competitive edge of BAIC BJEV, and facilitate the sales of its new energy vehicle parts.

Investment Thesis

In respect of share price catalysts, the company may benefit from two favorable news: 1) It is rumored that BAIC Motor is expected to establish a JV with Fiat Chrysler Automobiles NV (FCA). Apart from the Jeep brand, FCA owns a variety of classic SUV models including Chrysler and Dodge. If the rumor is true, we believe this will further diversify SUV model reserve of BAIC Motor, and allow BAIC Motor to more fully share benefits of the Chinese SUV consumption boom. 2) The Chinese government issued the Exposure Draft of Online Car-hailing Service Management, imposed very strict requirements on the parameters of new energy vehicles and eliminated most competitive models on the market. Yet, two types of BAIC Motor electric vehicles were short-listed and are projected to profit from the car-hailing service management. We lift the target price to HKD9.8 and maintain the rating to "Buy". (Closing price as at 17 October 2016)

Financials

Click Here for PDF format...




Recommendation on 20-10-2016
RecommendationBUY
Price on Recommendation Date$ 7.930
Suggested purchase priceN/A
Target Price$ 9.800
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+ 86 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre


Stock Borrowing & Lending



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong ½÷¥ß¬ã¨s³¡ ¡V ­»´ä¤Î¤¤°ê
Company Stock Code Last Update Suggestion Target Price Price on Recom
Information Techology Research Department N/A+852 2277 6527research@phillip.com.hk
O-Net Technologies87727/09/2016No Rating4.02
O-Net communications87726/10/2010BUY7.156
Transportation and Automobiles Zhang Jing (86) 2151699200-103zhangjing@phillip.com.cn
BAIC195820/10/2016BUY9.80 0.000
JAC60041813/10/2016Buy1813.88
Insurance Research Department (86) 21 51699400-110research@phillip.com.cn
Media & Publishing Research Department (+ 86 21 51699400-107)research@phillip.com.cn
Wisdom Sports Group166111/07/2016Buy3.32.18
NetDragon77716/06/2016Buy28.422.9
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Kangmei Pharmaceutical60051805/10/2016BUY20.116.22
China Traditional Chinese Medicine57013/09/2016Accumulate4.43.98
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Guangzhou Baiyunshan Pharma87418/10/2016Buy24.4819.16
Guangzhou Baiyunshan Pharma87417/10/2016Buy24.4819.16
New Energy Research Department (86) 21 51699400-110research@phillip.com.cn
SINGYES SOLA75014/10/2016Buy5.14.12
Yunnan Water683923/05/2016Buy5.73.94
Food, Beverage and Retail Research Department (86) 21 51699400-110research@phillip.com.cn
361 Degrees136126/08/2016Buy3.22.48
Poly Culture363625/08/2016Accumulate23.519.84
Telecommunications Fan Guohe + (86) 21 51699400-110fanguohe@phillip.com.cn
SMIC98128/09/2016Accumulate10.86
Byaa Interactive43405/07/2016Accumulate32.71
Mainland Property Research Department (86) 21 51699400-110research@phillip.com.cn
¤Ñ¼w¤Æ¤u60906/09/2016¼ÈµLµû¯Å1.95
Fortune REIT77823/08/2016No Rating9.65
Utilities Research Department (86) 21 51699400-110research@phillip.com.cn
HUADIAN FUXIN81607/10/2016Buy2.511.84
Dynagreen133026/09/2016Buy5.524.14
Software & Service Research Department (86) 21 51699400-110research@phillip.com.cn
Goldpac Group331518/02/2015N/A4.77
IGG800221/11/2014Accumulate3.953.44
Hotels and Entertainment Zhang Jing (+ 86 51699400-103)zhangjing@phillip.com.cn
Jinjiang Hotels200608/07/2016Accumulate2.982.49
CUTC60035808/03/2016N/A10.41

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2016 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]